CLINICAL TRIALS PROFILE FOR LAMOTRIGINE

505(b)(2) Clinical Trials for LAMOTRIGINE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00214877 ↗	Methylene Blue for Cognitive Dysfunction in Bipolar Disorder	Completed	Stanley Medical Research Institute	Phase 3	2003-11-01	While many bipolar patients treated with mood stabilizing medications experience improvement in their symptoms, some continue to have ongoing difficulties with concentration and memory. The purpose of this study is to look at whether these symptoms can be improved by adding the compound methylene blue to the treatment plan of patients who are already taking lamotrigine. Methylene blue is an available 'over the counter medication' in Canada. It has been studied in the long-term treatment of mood symptoms in bipolar disorder. Several clinical studies done in bipolar disorder report that methylene blue has had positive effects on both cognition and mood. It is important to do further research in this area as we know that, for patients who continue to have ongoing cognitive difficulties, there is no recognized standard of care for bipolar patients who experience these type of deficits.
OTC	NCT00214877 ↗	Methylene Blue for Cognitive Dysfunction in Bipolar Disorder	Completed	Nova Scotia Health Authority	Phase 3	2003-11-01	While many bipolar patients treated with mood stabilizing medications experience improvement in their symptoms, some continue to have ongoing difficulties with concentration and memory. The purpose of this study is to look at whether these symptoms can be improved by adding the compound methylene blue to the treatment plan of patients who are already taking lamotrigine. Methylene blue is an available 'over the counter medication' in Canada. It has been studied in the long-term treatment of mood symptoms in bipolar disorder. Several clinical studies done in bipolar disorder report that methylene blue has had positive effects on both cognition and mood. It is important to do further research in this area as we know that, for patients who continue to have ongoing cognitive difficulties, there is no recognized standard of care for bipolar patients who experience these type of deficits.

All Clinical Trials for LAMOTRIGINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000192 ↗	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00000192 ↗	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	Yale University	Phase 2	1993-01-01	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00001482 ↗	New Drugs in the Treatment of Mood Disorders	Completed	National Institute of Mental Health (NIMH)	Phase 2	1995-05-01	This clinical study compares the effectiveness of two anticonvulsants Lamotrigine (Lamictal) Monotherapy and Gabapentin (Neurontin) in patients with treatment resistant affective disorders. We initially have found that the response rate to lamotrigine (51%) exceeded that of gabapentin (28%) or placebo (21%). In this study the placebo phase has been dropped so that we examine possible clinical and biological factors predictors of response. The drugs will be given in a randomized order for six weeks each and you will not know when you are on a given one. There will be a 2-4 week "washout" period between treatments. If you respond well to one of these treatments, a longer open continuation period will be offered at the end of this study. This would involve one or both drugs in combination. A variety of rating scales and brain imaging procedures will also be offered before and during each drug evaluation. Both lamotrigine and gabapentin are generally well tolerated. A serious potentially life threatening rash occurs in about 1/500 patients treated with lamotrigine, however. Common side effects are rash, dizziness, unsteadiness, double vision, blurred vision, nausea, vomiting, insomnia, sedation, and headache. These side effects are usually mild, and resolve with continued time on the drug or a decrease in dosage.
NCT00006773 ↗	Bortezomib in Treating Patients With Recurrent Glioma	Terminated	National Cancer Institute (NCI)	Phase 1	2001-05-01	Phase I trial to study the effectiveness of bortezomib in treating patients who have recurrent glioma. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
NCT00007670 ↗	Does Gabapentin and Lamotriginel Have Significantly Fewer Side-Effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.	Completed	Glaxo Wellcome	Phase 3	1998-01-01	New onset epilepsy in the elderly occurs in 45,000-50,000 elderly patients each year. These patients are especially vulnerable to side effects from medications because of changes caused by the aging process and the fact that these patients often have many common diseases for which they are already receiving medications for so that the likelihood of drug interactions is increased. Two new drugs, gabapentin and lamotrigine, have recently been approved by the FDA as antiepileptic drugs. These drugs have demonstrated efficacy in the treatment of partial onset seizures, the most common seizures in the elderly. These new compounds also have favorable side effect profiles and infrequent drug-drug interactions and, therefore, would be expected to be well-tolerated in the elderly.

Clinical Trial Conditions for LAMOTRIGINE

Condition Name

Condition Name for LAMOTRIGINE
Intervention	Trials
Bipolar Disorder	54
Epilepsy	44
Healthy	20
Bipolar Depression	12

Condition MeSH

Condition MeSH for LAMOTRIGINE
Intervention	Trials
Bipolar Disorder	67
Epilepsy	55
Disease	41
Depression	39

Clinical Trial Locations for LAMOTRIGINE

Trials by Country

Trials by Country for LAMOTRIGINE
Location	Trials
United States	605
Germany	41
Canada	34
Italy	24
China	20

Trials by US State

Trials by US State for LAMOTRIGINE
Location	Trials
Texas	38
Ohio	33
New York	32
California	27
Pennsylvania	24

Clinical Trial Progress for LAMOTRIGINE

Clinical Trial Phase

Clinical Trial Phase for LAMOTRIGINE
Clinical Trial Phase	Trials
PHASE3	2
PHASE1	3
Phase 4	59

Clinical Trial Status

Clinical Trial Status for LAMOTRIGINE
Clinical Trial Phase	Trials
Completed	158
Terminated	19
Recruiting	15

Clinical Trial Sponsors for LAMOTRIGINE

Sponsor Name

Sponsor Name for LAMOTRIGINE
Sponsor	Trials
GlaxoSmithKline	59
National Institute of Mental Health (NIMH)	14
Dr. Reddy's Laboratories Limited	8

Sponsor Type

Sponsor Type for LAMOTRIGINE
Sponsor	Trials
Other	194
Industry	122
NIH	23

Lamotrigine Clinical Trials Update, Market Analysis, and 2026–2035 Forecast

Last updated: July 22, 2026

Lamotrigine is a mature, off-patent antiseizure and bipolar disorder drug with a large, established generic market in the US and EU. Current “clinical trials update” activity is dominated by incremental, investigator-led, and formulation or regimen optimization studies (including drug-drug interaction, pediatric epilepsy, and comparative tolerability endpoints) rather than late-stage new-molecular-entity development. Commercial upside is driven mainly by continued demand growth in epilepsy and bipolar-spectrum indications, plus margin and share competition among generics and switch-to-extended-release strategies in select geographies. No robust basis exists to project a material new-originator-driven market inflection from a single late-stage readout.

What clinical trials are ongoing for lamotrigine in epilepsy and bipolar disorder?

Lamotrigine’s clinical pipeline is best characterized as “optimization” and “real-world applicability” rather than breakthrough innovation. The most persistent trial themes are:

• Pediatric and adolescent epilepsy outcomes (seizure control, retention, rash/tolerability risk stratification).
• Comparative effectiveness and safety in specific seizure types and comorbidities.
• Treatment sequencing and monotherapy vs add-on in early disease courses.
• Drug-drug interaction trials in special populations (notably enzyme-inducing antiseizure medicines and valproate).
• Formulation and adherence-focused studies (controlled release or regimen simplification where approved).

Which endpoints show up most frequently?

Across lamotrigine epilepsy and bipolar studies, recurring primary or key secondary endpoints include:

• Seizure freedom rates at fixed intervals (often 8 to 24 weeks depending on design).
• Time to first seizure and responder rates (≥50% seizure reduction).
• Treatment discontinuation due to adverse events, with rash monitoring as a key safety measure.
• For bipolar disorder trials: time to recurrence of mood episodes and change in symptom scales for depressive or manic states.

What does “trial activity” imply for near-term product strategy?

For brand or generics, ongoing trial readouts usually translate into:

• Labeling refinements in subpopulations.
• Evidence for switching strategies (e.g., titration speed, adherence supports).
• Differentiation by tolerability narratives in marketing claims, even when active ingredient is unchanged.

How big is the lamotrigine market today and what drives demand growth?

Lamotrigine demand is anchored in chronic use for:

• Epilepsy (especially focal seizures and mixed seizure syndromes in many settings).
• Bipolar disorder maintenance, with additional use in bipolar depression in jurisdictions where approved or supported by practice patterns.

Demand drivers

The key structural drivers are:

• Long-duration treatment persistence for epilepsy.
• Global epilepsy prevalence trends and continued diagnosis and treatment access.
• Guideline-based use patterns in bipolar disorder maintenance.
• Generic availability expansion that increases access and lowers effective price.

Margin reality

Because lamotrigine is widely genericized, revenue growth tends to come from units and geographic access more than pricing power. In major markets, brand economics are typically limited to:

• Limited-risk branded share retention.
• Contracts tied to formulary positioning.
• Product differentiation via dosage strengths, pack sizes, or release form, not new active ingredient IP.

What is the 2026–2035 market projection for lamotrigine?

Baseline projection logic

A credible forecast for lamotrigine through 2035 typically decomposes into:

• Volume growth from epilepsy and bipolar maintenance demand.
• Price erosion from generic competition in the US, EU, and other regulated markets.
• Switching between immediate-release and any extended-release products where accessible and reimbursed.

Projection direction (not a single-number “hockey stick”)

Given the mature status of lamotrigine, the market outlook is typically:

• Positive unit growth through the decade.
• Low to mid single-digit compound revenue growth in mature markets where price erosion continues.
• Stronger growth in emerging markets driven by improved treatment access, with higher uncertainty around reimbursement and generic penetration speed.

When do lamotrigine exclusivity and patent protections expire, and do they still matter?

Lamotrigine is a long-established medicine; in most major jurisdictions, active-ingredient exclusivity for the original brand is already expired. As a result, competitive dynamics are driven by:

• Formulation-specific patents (if any remain in a given jurisdiction and claim scope).
• Method-of-use claims (rarely dominant compared with generic presence, but can support niche exclusivity in certain settings).
• Patent litigation history between generic manufacturers (often ending in settlement and generic entry timelines).

What this means for investors and licensors

In mature, off-patent products like lamotrigine, the practical leverage comes from:

• Local patent estates that still cover a particular formulation, strength, or dosing regimen.
• Litigation posture and any “skinny label” or delayed-entry settlements.
• Supply chain and manufacturing qualification, because generic switching is fast when legal barriers are cleared.

What is the Orange Book status of lamotrigine in the US?

Lamotrigine products in the US are widely listed as approved generic equivalents under multiple NDA/ANDA holders, with limited remaining relevance of new-originator exclusivity. The US market is primarily a generic competition marketplace, where:

• Product-level ANDA approvals control substitution.
• Exclusivity, where present, is usually tied to specific applicants’ paragraph IV outcomes or formulation-specific exclusivities rather than original active-ingredient protection.

How many patents cover lamotrigine, and what types are most common?

Across mature drugs with extensive generic presence, surviving patent families typically fall into a few categories:

• Formulation patents (e.g., release characteristics, excipient systems, stability).
• Method-of-use patents (e.g., patient subgroups, titration strategies, combination regimens).
• Manufacturing process patents (lower impact on generic entry unless claim scope blocks commercial manufacturing).

For lamotrigine specifically, market outcomes generally indicate that such patents have not prevented broad generic availability in most major markets.

Which companies dominate lamotrigine generics and what is the competitive landscape?

The competitive landscape is driven by large multi-product generic manufacturers plus regional players with strong distribution and formulary relationships. Dominance typically correlates with:

• Scale manufacturing and supply continuity.
• Ability to win formulary status through pricing and rebate structures.
• Portfolio breadth across strengths and package formats.

In practice, lamotrigine competitive advantage is mostly operational, not IP-led.

What paragraph IV challenges or patent litigations affect lamotrigine generic entry?

For mature small-molecule drugs like lamotrigine, patent litigation history generally:

• Occurs around earlier generic entry waves.
• Concludes with settlement-driven launch dates.
• Leaves behind a largely genericized baseline for later entrants.

As a result, near-term access to market share is typically less about ongoing paragraph IV cycles and more about supply, pricing, and local formulary dynamics.

How does lamotrigine compare with other antiseizure drugs on efficacy and tolerability economics?

Lamotrigine is positioned as:

• Effective for seizure control in many epilepsy phenotypes.
• Generally well-tolerated relative to some alternative antiseizure medications, with the known rash risk shaping titration practices.

From an economic standpoint:

• Generic pricing makes it a low-cost option versus newer antiseizure drugs.
• Clinical practice favors it when seizure type and patient factors align, since cost and long-term adherence matter.

What formulation and dosing innovation opportunities exist for lamotrigine now?

With the active ingredient mature and legal barriers largely cleared:

• New product development focuses on release engineering, dosing convenience, and stability.
• Differentiation is often “product design” rather than “new clinical capability.”

Examples of innovation pathways that commonly attract development (where regulatory and IP allow):

• Extended-release or modified-release approaches (in jurisdictions where such products are pursued).
• Pediatric-friendly dosing and palatability improvements (lower barrier to regulatory variation in some markets).
• Fixed-dose combination concepts with other antiseizure medicines (limited by the need for evidence and potential separate IP hurdles).

What biosimilar risk exists for lamotrigine?

None. Lamotrigine is a small molecule; biosimilar frameworks do not apply.

Revenue exposure: how exposed are portfolios to lamotrigine demand shifts?

For companies with significant antiseizure and psychiatric portfolios:

• Lamotrigine can be a volume anchor product.
• Revenue sensitivity is usually tied to generic price erosion and formulary share shifts rather than demand collapse.

For originators or specialty entrants:

• Exposure is typically lower due to genericization.
• Any remaining branded share is vulnerable to rapid substitution.

Key takeaways on clinical update and market outlook

• Lamotrigine clinical activity is dominated by incremental optimization and special-population evidence rather than new-molecular innovation.
• Market growth is expected to remain driven by unit demand and geographic access, with persistent price erosion in mature markets.
• Forecasting should focus on volume and competitive pricing dynamics, not a single late-stage clinical catalyst.
• Competitive advantage is operational (manufacturing scale, supply reliability, rebate/formulary execution), not IP-led.

Key Takeaways

• Lamotrigine is a mature, widely genericized antiseizure and bipolar maintenance drug with limited catalyst-driven upside.
• Clinical trials continue, mainly for epilepsy subgroups, pediatric outcomes, tolerability, and regimen optimization.
• Market projections through 2035 should assume positive volume growth offset by ongoing price erosion in established markets.
• Near-term competition is dominated by generic entrants and formulary dynamics rather than new exclusivity.

FAQs

1) What are lamotrigine’s most common clinical trial inclusion criteria in epilepsy studies?
Typical enrollment centers on stable titration feasibility, defined seizure phenotype windows, and measurable seizure endpoints over fixed follow-up periods.

2) Does lamotrigine require specific drug-drug interaction monitoring in trials?
Trials routinely incorporate monitoring and stratification around enzyme inducers and valproate due to predictable pharmacokinetic effects.

3) What endpoint best predicts lamotrigine continuation in long-term studies?
Discontinuation due to adverse events and responder maintenance at fixed intervals are frequently used as continuation predictors.

4) Why does lamotrigine revenue track generic pricing more than clinical readouts?
Because the active ingredient is widely genericized, product pricing and formulary positioning drive revenue more than marginal evidence updates.

5) Are there any realistic near-term market differentiators for lamotrigine beyond generics?
Differentiation is most likely to come from formulation convenience, packaging, adherence tools, and local regulatory or settlement-driven constraints, not new active-ingredient IP.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-22).
2. ClinicalTrials.gov. Lamotrigine search results and study listings. (Accessed 2026-07-22).
3. EMA. European public assessment reports and product information for lamotrigine-containing medicines. (Accessed 2026-07-22).